FHTX Foghorn Therapeutics Inc.

8-K Current Report

Filed: February 23, 2026

Health Care

Pharmaceutical Preparations

Foghorn Therapeutics Inc. (FHTX) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 5.02: Departure/Election of Directors or Officers
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

• Ryan D. Maynard appointed CFO effective Feb 23, 2026; replaces interim CFO Jeff Sacher
• Base salary $510,000 with 40% target annual bonus (~$204,000) and $90,000 signing bonus

+3 more insights

Item 8.01 · Other Events

• Press release filed Feb 23, 2026 announcing management changes — details in Exhibit 99.1
• Leadership transitions at clinical-stage biotechs can signal strategic pivots or pipeline reprioritization

Other Foghorn Therapeutics Inc. 8-K Filings

8-K Mar 11, 2026

Get deeper insights on Foghorn Therapeutics Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.